{"title":"[Study on the Mechanism of Yiqi Chutan Recipe in the Treatment of Lung Cancer with Splenasthenic Syndrome].","authors":"Yu-lin Wei, Shu-mei Wang, Qi-ou Liu, Yang Luo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the mechanism of Yiqi Chutan recipe( YCR) in the treatment of lung cancer with splenasthenic syndrome from the perspective of the endoplasmic reticulum stress( ERS).</p><p><strong>Methods: </strong>60 mice were successfully modeled as Lewis lung cancer mice with spleen deficiency, which were randomly divided into model group( normal saline),cisplatin group( 1 mg / kg),low dose( 2 g/kg) YCR group, middle dose( 4 g/kg) YCR group,high dose( 8 g/kg) YCR group and the combined medication group( YCR 4 g/kg + cisplatin 1 mg / kg),with 10 mice in each group. The mice were killed after 14 days,the size and weight of tumor in mice were measured,morphological changes of tumor were observed by HE staining method, the expression of CHOP and DR5 protein in tumor tissue was detected by immunohistochemical method and Western blot method.</p><p><strong>Results: </strong>Compared with model group, the volume and weight of tumor in cisplatin group, middle dose YCR group, high dose YCR group and combined medication group were significantly decreased( P < 0. 01),and the tumor cells in transplanted tumor were large necrosis and the protein expression of CHOP and DR5 were increased significantly( P < 0. 01). The effect in treatment of lung cancer with splenasthenic syndrone in combined medication group was higher( P < 0. 05 or P < 0. 01).</p><p><strong>Conclusion: </strong>Yiqi Chutan recipe has different degrees of inhibition on lung cancer, the combined use of cisplatin can obviously improve the curative effect. The mechanism may be related to up-regulating the expression of CHOP and DR5 in endoplasmic reticulum stress-related proteins.</p>","PeriodicalId":15312,"journal":{"name":"中药材","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中药材","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the mechanism of Yiqi Chutan recipe( YCR) in the treatment of lung cancer with splenasthenic syndrome from the perspective of the endoplasmic reticulum stress( ERS).
Methods: 60 mice were successfully modeled as Lewis lung cancer mice with spleen deficiency, which were randomly divided into model group( normal saline),cisplatin group( 1 mg / kg),low dose( 2 g/kg) YCR group, middle dose( 4 g/kg) YCR group,high dose( 8 g/kg) YCR group and the combined medication group( YCR 4 g/kg + cisplatin 1 mg / kg),with 10 mice in each group. The mice were killed after 14 days,the size and weight of tumor in mice were measured,morphological changes of tumor were observed by HE staining method, the expression of CHOP and DR5 protein in tumor tissue was detected by immunohistochemical method and Western blot method.
Results: Compared with model group, the volume and weight of tumor in cisplatin group, middle dose YCR group, high dose YCR group and combined medication group were significantly decreased( P < 0. 01),and the tumor cells in transplanted tumor were large necrosis and the protein expression of CHOP and DR5 were increased significantly( P < 0. 01). The effect in treatment of lung cancer with splenasthenic syndrone in combined medication group was higher( P < 0. 05 or P < 0. 01).
Conclusion: Yiqi Chutan recipe has different degrees of inhibition on lung cancer, the combined use of cisplatin can obviously improve the curative effect. The mechanism may be related to up-regulating the expression of CHOP and DR5 in endoplasmic reticulum stress-related proteins.
期刊介绍:
"Chinese Materia Medica" magazine was founded in 1978. It is a national-level academic journal of Chinese medicine science and technology approved by the State Science and Technology Commission and the Press and Publication Administration for public distribution at home and abroad. It is sponsored by the Chinese Materia Medica Information Center of the State Food and Drug Administration and is publicly distributed at home and abroad. It mainly reports on new technologies, new methods and new achievements in the production, scientific research and business management of Chinese medicine, and serves to promote the production and scientific and technological development of Chinese medicine, improve the output and quality of Chinese medicine, improve business management, and prosper the Chinese medicine industry.